Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- MHLW’s FY2013 Budget Request Seeks More Funding Aimed at Reducing the Drug Lag Based on Results of Policy Evaluation
October 18, 2012
- MHLW to Compile New Generic Share Goal, Roadmap within FY2012
October 17, 2012
- Generic Substitution Could Save 1.53 Trillion Yen in Healthcare Spending: MOF
October 17, 2012
- Former Health Minister Nagatsuma to Take Over as Chairman of Lower House Committee on Health, Labor and Welfare
October 17, 2012
- Mochida’s Epadel Hastily Added to Review List for PAFSC’s Committee on Non-Prescription Drugs
October 16, 2012
- Gov’t, Municipalities Aim to Conclude Discussions on Funding for 3 Add’l Vaccines by Year End
October 16, 2012
- PAFSC’s 1st Committee to Review 4 Products Including Pfizer’s Toviaz on Oct. 26
October 15, 2012
- MEXT Requests Budget for Boosting Number of Pharmacists, Promoting Generic Use at National University Hospitals
October 15, 2012
- Trilateral Meeting of Health Ministers to Be Postponed After China Cites Inability to Attend
October 15, 2012
- MHLW to Begin Pilot Study on Drug Risk Management Plans for Generics
October 12, 2012
- Discussions on Cost-Effective Assessments Are for Preserving National Health Insurance System: Parliamentary Secretary Umemura
October 11, 2012
- Results of Paper-Based Inspection of Japan’s Application for Membership in PIC/S to Be Reported Next May
October 10, 2012
- Dr Takenaka Tapped as NIBIO Advisor, Committed to Creation of Drug Discovery Network
October 9, 2012
- Senior Vice Minister of Health Sakurai Stresses Need to Rebuild Ties with JMA
October 9, 2012
- Health Minister Mitsui Hopes to Ban All Forms of Dispensing Point Services Including Those Using Credit Cards
October 9, 2012
- MHLW to Request Development of 5 Drugs/Indications Determined to Have Unmet Medical Needs
October 5, 2012
- Ministry-Wide Discussions on Generics Necessary: Parliamentary Secretary Umemura
October 4, 2012
- Senior Vice Minister Sakurai Calls for Industry-Growth Perspective on Long-Listed Drug Pricing
October 4, 2012
- MHLW Issues Notification for Precautions in Use of Methapain
October 4, 2012
- Minister of Health Mitsui Sees Need for Cross-Agency Efforts to Promote New Drug Development
October 4, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…